Do antiplatelets and anticoagulants have an impact on the clinical outcomes of robotic ventral hernia repair?

Background: We sought to study the impact of antithrombotics(antiplatelets and anticoagulants) on robotic ventral hernia repair(RVHR). Methods: RVHR cases were divided into antithrombotic (AT) () and AT (+) groups. After comparing both groups, a logistic regression analysis was performed. Results: 611 patients had no AT-medication. The AT(+) group had 219 patients of which 153 were only on antiplatelets, 52 only on anticoagulants, and 14(6.4%) patients on both antithrombotics. Mean age, American Society of Anesthesiology scores, and comorbidities were significantly higher in the AT(+) group. Intraoperative blood loss was greater in the AT(+) group. Postoperatively, the AT(+) group had greater rates of Clavien-Dindo grade-II and IV-a complications(p=0.001, and p=0.013, respectively), and postoperative hematomas(p=0.013). Mean follow-up was greater than 40 months. Age[Odds Ratio(OR): 1.034] and anticoagulants(OR: 3.121) were associated with increased bleeding-related events. Conclusion: There were no associations between maintained antiplatelet therapy and postoperative bleedingrelated events in RVHR whereas age and anticoagulants had the highest association.